Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • milesgr
    Member
    • Jun 2010
    • 34

    #1

    GATK variant calling statistics...

    Hi all,
    We are calling variants on partial exome data using GATK. We want to see what fraction of our samples have a particular variant. As constituted, GATK will give us the set of samples containing the particular variant. Any sample that doesn't will simply exclude it from the VCF. My question is whether or not there is a way to distinguish the samples that have a true wild-type phenotype (and thus no variant call) from those that aren't called due to poor quality score (and thus should be excluded from our percentages since the phenotype cannot be determined). Thank you very much in advance for your help.
  • vdauwera
    Member
    • Apr 2012
    • 43

    #2
    There are two ways to deal with this. One is to use the EMIT_ALL_SITES option of UnifiedGenotyper and enable calculation of reference PLs. The other, which is better, is to call variants with HalpotypeCaller (GATK's newer variant caller) and use the -ERC option to generate a gVCF.

    For more details, see the online GATK documentation and please post any follow-up questions on the GATK support forum.

    http://www.broadinstitute.org/gatk/guide/
    http://gatkforums.broadinstitute.org/

    Comment

    Latest Articles

    Collapse

    • SEQadmin2
      Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
      by SEQadmin2



      CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

      Despite this, “CRISPR helped turn genome editing from a specialized technique into
      ...
      07-31-2026, 11:01 AM
    • SEQadmin2
      Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
      by SEQadmin2


      Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

      The systematic characterization of the human proteome has
      ...
      07-20-2026, 11:48 AM

    ad_right_rmr

    Collapse

    News

    Collapse

    Topics Statistics Last Post
    Started by SEQadmin2, 08-06-2026, 07:41 AM
    0 responses
    14 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 08-03-2026, 10:13 AM
    0 responses
    31 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-31-2026, 02:55 AM
    0 responses
    40 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-24-2026, 12:17 PM
    0 responses
    26 views
    0 reactions
    Last Post SEQadmin2  
    Working...